Yeah, with regards to antibiotics, I mean, I, you know, there's really two settings, right? There's the acute exacerbation setting, um, and, you know, we're using oral, uh, or IV or sometimes both antibiotics to treat that exacerbation for two weeks, usually, sometimes three weeks. Um, and that, and that's really a strategy to quell the exacerbation. It, it's also, you know, something we know that, you know, we're probably not going to, Uh, remove the organism or eradicate the organism. We're just trying to beat it down as much as we can and alleviate the patient's symptoms as much as we can and diminish the inflammation that's there. Um, the other way we use antibiotics are, of course, you know, I was talking about the developmental programs before. I mean, we, we spent a long time with various inhaled antibiotics trying to, um, evaluate how well they worked in terms of reducing bacterial load in the airway and then ultimately reducing, Uh, the frequency or instance of, uh, flare-ups or exacerbations. Um, there's no question that most inhaled antibiotic products, uh, do that. I mean, if you do a meta-analysis, um, which we did recently, um, in the ERS guidelines, which, uh, I was, uh, had the privilege to help the Europeans update. Um, and other people have done these meta analyses. It's very clear that, you know, inhaled antibiotics work. Um, pretty much every one that went through development showed some measure of efficacy in reducing exacerbations, 15 to 25%, somewhere in there. Sometimes better, sometimes less. Um, some of those trials were discordant, but when you put them together, I mean, it was very clear that there, there was efficacy with Colston and. Gentamicin, and Tova, etc. So, I, there's, there's no question that those products, um, can be useful. We, we do use them. Um, I have a number of patients on inhaled antibiotics, probably 15 to 20% of my patients. Of course, I'm at a, uh, uh, you know, a, a quote unquote expert center, you know, a tertiary referral center, so a higher percentage of our, our patients need that kind of therapy. You know, in that, in the community setting, it's much, much lower. It's probably more like 5% or less, uh, Bronchiectatics are on that kind of therapy. But suffice it to say it can be useful. It can break the cycle around exacerbation. It can reduce the frequency of exacerbation, probably not too much differently than Brenzo does in terms of the, the, the, the percentage reduction or the relative reduction. Um, so it does bring up the idea that, you know, maybe in some of these patients, we're going to be using them together. So, I, I think, sure, I already have patients that are on Brenzo and inhaled antibiotics, and that ultimately might be the best thing for, for the most severe patients. I think it will depend on what they're colonized with, what organisms are driving their underlying inflammatory milieu. I mean, certainly Pseudomonas is, Is the one we're, we're often targeting, but there's other bugs, a Chromobacter, tenotrophomonas, etc. I mean, um, some, some of these are more virulent than others in terms of their ability to cause, cause exacerbation. So, that might change which inhaled antibiotic you use based on, you know, what bugs the patient's growing. Um, we haven't talked about NTM. That's a whole another bailiwick of, uh, I'd like to say an endotype of bronchiectasis. A lot of people have NTM and pseudomonas, and they, they bounce back and forth depending on which one you're targeting. Um, so, you know, it, it can get really complicated with some of these patients, but to, to answer your question, yes, inhaled antibiotics will, will always be, as far as I can see, an important, um, tool in the toolkit.
Presenter
